3 recruiting, 3 unknown, 2 not yet recruiting, 1 active not recruiting. 4 Not applicable, 4 Phase 3, 2 Phase 1, 2 Phase 2.
Follow cTACE: new trials by email Literature Review of cTACE trials Research Report on cTACE
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Sequential FOLFOX-HAIC-TACE Plus Sintilimab-Bevacizumab Neoadjuvant Therapy Versus Direct Resection in Resectable High-Risk Recurrence Hepatocellular Carcinoma FOLFOX regimen, Immunotherapy, targeted therapy - Hepatocellular Carcinoma | Phase 1 / Phase 2 | Not yet recruiting | BinYong Liang | 100 | 2026-04-30 | 2026-04-13 |
| DEB-TACE vs cTACE in HCC After TIPS DEB-TACE, cTACE - Hepatocellular Carcinoma (HCC), TACE | Phase 3 | Recruiting | First Affiliated Hospital, Sun Yat-Sen University | 206 | 2025-12-01 | 2026-05-01 |
| A Study of Yttrium [90Y] Microsphere Injection in Combination With Targeted Immunotherapy in the Treatment of HCC Yttrium [90Y] Microsphere Injection, Conventional transcatheter arterial chemoembolization, Camrelizumab - HCC | Phase 2 | Recruiting | GrandPharma (China) Co., Ltd. | 120 | 2025-08-22 | 2026-01-12 |
| Chinese HCC Efficacy Evaluation, Response and Safety Study of TareSphere NRT6003 Injection, cTACE - Unresectable Hepatocellular Carcinoma | Phase 3 | Active not recruiting | Chengdu New Radiomedicine Technology Co. LTD. | 108 | 2025-04-15 | 2026-06-09 |
| SIRT Versus cTACE for Unresectable HCC (CHANCE2506) SIRT, cTACE - Unresectable Hepatocellular Carcinoma | Not applicable | Recruiting | Zhongda Hospital | 108 | 2025-04-03 | 2025-04-09 |
| A Clinical Trial Assessing the Safety and Efficacy of Biodegradable Magnesium Embolic Microspheres for Primary Hepatocellular Carcinoma Magnesium Microspheres, cTACE - Hepatocellular Carcinoma Non-Resectable | Phase 3 | Not yet recruiting | InnoBM Pharmaceuticals Co., Ltd. | 228 | 2025-01-01 | 2025-01-16 |
| TACE With Dicycloplatin(TP21) in Unresectable HCC cTACE, Dicycloplatin (TP21), Epirubicin - Hepatocellular Carcinoma | Phase 3 | Unknown | Gao-jun Teng | 332 | 2022-06-09 | 2022-07-25 |
| A Study on the Safety and Effectiveness of IBI318 Combined With Conventional TACE (cTACE) as a Perioperative Treatment for Potentially Resected Hepatocellular Carcinoma IBI318, cTACE, placebo - Hepatocellular Carcinoma | Phase 1 | Terminated | Innovent Biologics (Suzhou) Co. Ltd. | 10 | 2020-12-24 | 2023-03-16 |
| Drug-eluting Bead Transarterial Chemoembolisation (DEB-TACE) Versus (VS) Conventional Transarterial Chemoembolisation (cTACE) for Unresectable Hepatocellualr Carcinoma (HCC) DEB-TACE, cTACE - Hepatocellular Carcinoma | Not applicable | Unknown | Air Force Military Medical University, China | 344 | 2020-09-15 | 2020-02-05 |
| Efficacy and Safety of TACE on Downstaging Hepatocellular Carcinoma Beyond UCSF Criteria; DEB-TACE, cTACE, Drug-eluting Beads - Hepatocellular Carcinoma | Not applicable | Unknown | Beijing Tsinghua Chang Gung Hospital | 226 | 2020-03-18 | 2021-02-04 |
| Emulsion Versus Suspension in Chemoembolization for Hepatocellular Carcinoma Lipiodol-based transarterial chemoembolization - Hepatocellular Carcinoma | Not applicable | Completed | Chinese University of Hong Kong | 80 | 2016-09-09 | 2024-11-15 |
Air Force Military Medical University, China (1) · Beijing Tsinghua Chang Gung Hospital (1) · BinYong Liang (1) · Chengdu New Radiomedicine Technology Co. LTD. (1) · Chinese University of Hong Kong (1) · First Affiliated Hospital, Sun Yat-Sen University (1) · Gao-jun Teng (1) · GrandPharma (China) Co., Ltd. (1) · InnoBM Pharmaceuticals Co., Ltd. (1) · Innovent Biologics (Suzhou) Co. Ltd. (1) · Zhongda Hospital (1)
China (9) · Hong Kong (1)
Gao-Jun Teng (1) · Gao-Jun Teng, Doctor (1) · Gaojun Teng (1) · Simon Yu (1) · Zhiping Yan, MD (1)